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A B S T R A C T
The gut microbiome comprises the community of microorganisms in the intestinal tract. Research suggests that an altered microbiome may play a role in a wide
range of disorders including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Methods: 42 participants with ME/CFS with Irritable Bowel Syndrome (IBS) were allocated into one of two groups, 21 were treated with standard oral approaches,
which centred around various nutritional remedies, probiotics, prebiotics, dietary advice and lifestyle advice. The second group who had mostly failed using oral
approaches, were treated with Faecal Microbiome Transplantation (FMT). Each patient received 10 Implants, each from a different screened donor, and the Implants
were processed under anaerobic conditions. The transplant is delivered via a paediatric rectal catheter, which is inserted through the anus to reach the lower part of
the sigmoid colon.
The results were assessed on a percentage basis before and after treatment, 0% being no improvement, 100% being maximum improvement. An exact non-
parametric Mann-Whitney (one-tailed) test was used to compare medians from those on FMT compared with those receiving oral approaches only. On clinical
experience over many years, the only way to judge improvement in Chronic Fatigue Syndrome as there is no test for Chronic Fatigue Syndrome, is my clinical
assessment.
Results: The median for the FMT group was found to be significantly higher compared to the oral treatment group (Mann-Whitney U=111.5, p= .003). Therefore,
the FMT group improved to a greater extent (z=−2.761).
Conclusion: This study shows that FMT is a safe and a promising treatment for CFS associated with IBS. Adequately powered randomised controlled trials should be
carried out to assess the effectiveness of FMT in patients with CFS and IBS.
1. Introduction
The gut microbiome comprises the community of microorganisms in
the intestinal tract. Over the last five years, interest in the gut micro-
biome has grown considerably driven by new techniques in DNA se-
quencing allowing for characterisation of gut bacteria and the recogni-
tion of the potential impact the microbiome may have on health [1,2].
The large intestine has the highest number of microbial organisms, with
less found in the more hostile low-pH environment of the small intes-
tine. The large intestine is dominated by anaerobic bacteria which
survive and thrive by anaerobically digesting our food [3–5]. The gut
microbiome has coevolved with humans to match our modern lifestyles
[6] and is beneficial for our health, supplying essential nutrients, syn-
thetizing vitamins (i.e. vitamin K) and facilitating digestion of un-
digested carbohydrates [7–9]. Furthermore, bacteria also help maintain
the integrity of the mucosal barrier by preventing antigens and
pathogens entering the gut mucosa [10,11].
In healthy adults, 80% of the identified faecal microbiota can be
classified into three dominant phyla: Bacteroides, Firmicutes and
Actinobacteria. In general terms, the Firmicutes to Bacteroides ratio is
regarded to be of significant relevance in the human gut microbiota
composition. High Firmicutes and low Bacteroides usually correlates
with a healthy diverse microbiome and reflects a largely plant-based
diet. In unhealthy microbiomes the opposite is the case and may well be
due to a more western type diet [12,13]. Alterations in the composition
of the microbiome has the potential to significantly impact on our
health and wellbeing. One of the side effects of antibiotic use is a
change in gut microflora that allows overgrowth of harmful micro-or-
ganisms [14]. Clostridium Difficile-associated diarrhoea for example is
a well-recognised infection linked to previous antibiotic use [15]. Fur-
thermore, studies on young children with a developing microbiome
have shown that antibiotics are especially likely to cause long lasting
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adverse changes [16–18]. Regulation of the gut flora has also been
correlated with a host of inflammatory and immune conditions [19,20].
Recent changes in lifestyle including reduced exposure to pathogens in
early life, dietary changes to a high intake of carbohydrates and fats
from processed foods and reduced dietary fibre have been proposed to
play a role in the rise of inflammatory conditions such as inflammatory
bowel disease (IBS/D) and Crohn’s disease [19,20]. The microbiome
has been shown to have profound effects in the development of gut-
associated lymphoid tissue, differentiation of gut immune cells and
production of immune mediators such as IgA’s and microbial defence
peptides [21]. Recent research suggests that an altered microbiome
may play a role in a wide range of disorders including Parkinson’s
disease [22,23] chronic liver disease [24,25], myalgic en-
cephalomyelitis/chronic fatigue syndrome (ME/CFS) [26,27] and also
impact cancer patient recovery after treatments such as chemotherapy
and radiotherapy [28].
In this study we randomly chose 21 patients from our sizeable po-
pulation of Chronic Fatigue Syndrome patients. These patients were
treated using oral approaches and also lifestyle and dietary advice.
Then, 21 patients with Chronic Fatigue Syndrome who were treated
with Faecal Microbiome Transplantation (FMT).
2. Materials and methods
All our Chronic Fatigue Syndrome patients were assessed using the
agreed international consensus criteria for Chronic Fatigue Syndrome
and Myalgic Encephalomyelitis [29].
Other possible diagnoses in all of these patients were ruled out with
appropriate clinical examination and appropriate investigations by
their General Practitioners prior to seeing us.
We divided the patients into two groups of 21 per group. 21 were
treated with standard oral approaches, which centred around various
nutritional remedies, probiotics, prebiotics, dietary advice and lifestyle
advice. The second group were treated with FMT and the second group
had mostly failed using oral approaches.
In the Faecal Microbiome Transplantation population in this study,
each patient was implanted with 10 Implants, each from a different
screened donor and we have found in clinical practice that 10 Implants
is an optimal number, the Implants are processed under anaerobic
conditions. The criteria for Chronic Fatigue Syndrome is as per
Carruthers BM, van de Sande MI, et al. [29].
Donors are screened and undergo testing for many common com-
municable diseases to ensure that the procedure is done as safely as
possible, but it is not possible to test donors for all possible organisms
and some infections may be undetectable. To date there have not been
any documented cases of an infection transmitted through FMT. The
donor verifies that he/she has no history of:
1. Risky sexual behaviour
2. Use of illicit drugs
3. Tattoos or piercings in the last six months
4. Communicable disease
5. Metabolic syndrome (overweight, high blood pressure, fatty liver
and/or Diabetes)
6. Any type of Cancer or active Autoimmune Disease
7. Risk factors for acquisition of HIV, Syphilis, Hepatitis B, Hepatitis
C, Prion Infection or any Neurological Disease
8. Gastrointestinal comorbidities: e.g. Inflammatory Bowel Disease,
Irritable Bowel Syndrome, Chronic Constipation or Diarrhoea
9. Receipt of Blood Transfusion in the preceding six months
10. Antibiotic use or any systemic immunosuppressive agent in the past
three months prior to stool donation
11. Receipt of any type of Live Vaccine within three months prior to
stool donation
12. Chemotherapy in the last three months.
The donor/donor blood sample is screened for:
Human Immunodeficiency Virus (HIV) 1/2, Hepatitis A. IgM,
Hepatitis B (HBsAg), Hepatitis C antibody, Syphilis, IgG/IgM, Full
Blood Count, Urea and Electrolytes, Ferritin, C-Reactive Protein, Tissue
Transglutaminase, CMV, H-Pylori.
The Donor’s Stool Sample has been tested for:
Campylobacter (Jejuni, Coli and Upsalliensis), Clostridium Difficile
(A/B), Salmonella, Yersinia Enterocolitica, Vibrio (Parahaemolyticus
Vulnificus and Cholera), Diarrhoea-causing E-Coli/Shigella,
Enteroaggregative E-Coli (EAC), Enteropathogenic E-Coli (EPEC),
Enterotoxigenic E-Coli (ETEC), Shiga-like toxin-producing E-Coli
(STEC), E-Coli 0157, Shigella/Enteroinvasive E-Coli (EIEC),
Cryptosporidium, Cyclospora Cayetanesis, Entamoeba Hystolitica,
Giardiolambia, Adenovirus, Astrovirus, Norovirus GI/GLL, Rotavirusa,
Sapovirus.
We used Implants supplied by The Taymount Laboratory https://
taymount.com/.
The results were assessed on a percentage basis before and after
treatment, 0% being no improvement, 100% being maximum im-
provement. In no case did we obtain more than a 95% response. This is
a clinical judgement as there is no objective test for Chronic Fatigue
Syndrome.
Essentially, FMT represents the transfer of the faecal microbiota
from healthy donors to diseased recipients in order to restore a ba-
lanced gut microbial ecology, and in turn foster resolution of symptoms.
A liquid suspension of homogenised stool is instilled into the sig-
moid colon using a paediatric catheter [Table 2]. Every patient in this
study signed an Informed Consent allowing anonymous use of their
data.
One patient reacted to several of the implants with diarrhoea, so we
had to stop the implants. One other patient only managed to tolerate
half of the implants. Other than that, there were no other adverse ef-
fects from the treatment.
3. Analysis
The data were tested for normality and an exact non-parametric
Mann-Whitney (one-tailed) test was used to compare medians from
those on FMT compared with those receiving oral approaches only.
4. Results
The results are attached in Tables 1 and 2.
The median for the FMT group was found to be significantly higher
compared to the oral treatment group (Mann-Whitney U=111.5,
p= .003). Therefore, the FMT group improved to a greater extent
(z=−2.761).
5. Discussion
Chronic Fatigue Syndrome is relatively common [30]. Chronic Fa-
tigue Syndrome is often a co-morbid clinical condition with Irritable
Bowel Syndrome [31,32].
We know that in the microbiome of Chronic Fatigue Syndrome
patients the intestinal microbiome is abnormal [33,34]. Essentially,
FMT represents the transfer of the faecal microbiota from healthy do-
nors to diseased recipients in order to restore a balanced gut microbial
ecology, and in turn foster resolution of symptoms [35]. FMT has been
used for many years for the treatment of Clostridium Difficile (CDiff)
and more recently for conditions such as Irritable Bowel Syndrome and
Ulcerative Colitis with significant studies published to support these
uses [36].
The notion of the faecal transplant as a therapeutic invention is not
new, as this procedure was first performed almost two millennia ago by
a Chinese Medical Scientist named Ge Hong [37].
Compared to Probiotics, which act temporarily, the satisfactory
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outcome of treatment with FMT suggests that faeces contain a superior
combination of intestinal bacterial strains and is more favourable for
repairing disrupted native microbiota by introducing a complete, stable
community of intestinal micro-organisms [38].
Likewise, faeces contain other factors, proteins, vitamins and bile
acids, which may enhance gut recovery [39].
A recent very interesting study shows that in patients with Irritable
Bowel and Chronic Fatigue Syndrome, there is an authentic blood mi-
crobiome in non-communicable diseases. The chief origin of these mi-
crobes is the gut microbiome (especially when it shifts composition to a
pathogenic state known as (Dysbiosis’).
This study has significant limitations as it is a retrospective
Observational Outcomes Study, it is not a Randomised Control Trial.
The aim is to encourage proper Randomised Control Studies to be
carried out in this area, because our Observational Outcomes Study
here showed benefits amongst many patients, so this area is worth in-
vestigating further.
From our current study and from the effectiveness of Faecal
Microbiome Transplantation, it would appear that this hypothesis is the
first event that can result in Chronic Fatigue Syndrome associated with
Irritable Bowel Syndrome [40].
6. Conclusion
Faecal Microbiome Transplantation is a safe, and from this study, an
encouraging treatment for Chronic Fatigue Syndrome associated with
Irritable Bowel Syndrome. This study argues for carrying out a
Randomised Controlled Study of Chronic Fatigue Syndrome and
Irritable Bowel Syndrome patients.
Table 1
Chronic Fatigue Syndrome patients treated with FMT.
Patient % Improved
(F) Age 36 Severe Chronic Fatigue Syndrome with Irritable Bowel Syndrome for three years, following multiple antibiotics for Quinsy. Severe debilitating
Irritable Bowel, with lack of energy. She had FMT in February 2018, following this the Irritable Bowel cleared up, energy significantly better. Has
always had many food sensitivities, they are gradually beginning to resolve. A further course of FMT is under consideration.
70%
(F) Age 40 Polycystic Ovary Syndrome, also Irritable Bowel and a Chronic Fatigue. She had FMT in October 2017, following the FMT her energy is much
improved and is practically normal, has remained so ever since. Also, her mood is more stable.
90%
(F) Age 59 Severe Vaginal Thrush for five years, recurrent abdominal bloating, Irritable Bowel Syndrome and Chronic Fatigue Syndrome. Clostridium Difficile in
2013. She had FMT in May 2017, two months after FMT the Irritable Bowel cleared up completely, her skin is significantly better than it was prior to
treatment, Vaginal Thrush is still something of a problem, but not as bad as it was. She finds she is no longer craving sweet foods.
90%
(F) Age 73 History over many years of Irritable Bowel Syndrome and Chronic Fatigue Syndrome, also overweight. We treated her with FMT in December 2017,
the Irritable Bowel Syndrome cleared up during the two months following the FMT and has remained normal. She is still having difficulty in losing
weight.
60%
(F) Age 43 Several years history of Chronic Fatigue Syndrome. Also, Irritable Bowel Syndrome. We carried out FMT in January 2017, since that time the IBS has
cleared up, energy significantly improved and has remained so.
70%
(F) Age 42 8-year history of Chronic Fatigue Syndrome. Also, Irritable Bowel Syndrome. We treated her with FMT in November 2018, I first saw her in May
2018. Since the FMT her persistent Oral Thrush has cleared, her digestion has improved, and the Irritable Bowel has settled down. She is no longer
constipated. Her energy improved almost to normal following the FMT but has had a bit of a relapse since significant family upset, which has been
draining on her energy reserves.
95%
(F) Age 73 Insomnia, persistent Nausea, poor energy due to Chronic Fatigue Syndrome, lack of appetite. Has lost a great deal of weight over several years.
Complains of bad body odour. We carried out FMT in February 2017. Since then the Nausea has disappeared, the appetite has returned, and she is
now putting on weight.
95%
(F) Age 46 I first saw her in 2016 with a history of Chronic Fatigue Syndrome and Fibromyalgia for several years. We carried out FMT in January 2017, no
significant response to the FMT. We are thinking of repeating the FMT.
0%
(F) Age 66 At the age of 26 this patient contracted amoebiasis in the Himalayas, then she had lots of antibiotics for various indications and has had Irritable
Bowel Syndrome and Chronic Fatigue Syndrome since the age of 30. Also, she has been diagnosed with SIBO and had developed multiple food
sensitivities. We carried out FMT in July 2017, her Irritable Bowel Syndrome normalised over the next four weeks, her energy improved and became
normal, then she had exposure to contaminated water, probably containing parasites, then she relapsed to some extent and had to have a second
course of FMT in December 2017. Since that time, she has been completely normal.
95%
(F) Age 47 This patient has had regular courses of antibiotics since the age of 12 for a range of reasons. She has had many years of Chronic Fatigue and Irritable
Bowel Syndrome. We carried out FMT in August 2018, since then the Irritable Bowel has settled down and the Chronic Fatigue has resolved.
90%
(F) Age 73 This patient has had a history of recurrent Candidiasis over many years, including Oral Thrush. She has many years history of Irritable Bowel
Syndrome and Chronic Fatigue Syndrome. We carried out FMT on her in November 2018. Since that time, she has had no more Candidiasis, the
Irritable Bowel has settled down, and there is significant maintained improvement in her energy levels.
85%
(F) Age 70 This patient has had a history over many decades of a Chronic Fatigue Syndrome. We used FMT in April 2017, there was no improvement in her
energy levels since the FMT.
0%
(F) Age 70 Chronic Fatigue Syndrome for 20 years, also Addison’s Disease, Fibromyalgia and Irritable Bowel Syndrome. FMT carried out in August 2018. She
reacted to several of the Implants with Diarrhoea, so we had to stop the Implants. Clinically, no change.
0%
(F) Age 61 20-year history of Chronic Fatigue Syndrome and Fibromyalgia, also Irritable Bowel Syndrome. Oral treatment did not work. FMT was carried out in
April 2018. Following FMT her energy improved dramatically and has remained improved. The Irritable Bowel Syndrome has cleared up and she also
lost one and a half stone in weight.
90%
(F) Age 41 Many years history of Chronic Fatigue Syndrome, multiple food sensitivities and Irritable Bowel Syndrome. FMT carried out in September 2018. She
managed to tolerate half of the Implants and then temporarily had to stop. No clinical improvement yet.
0%
(F) Age 44 Eight-year history of Chronic Fatigue Syndrome getting significantly worse. Also, Irritable Bowel Syndrome. We carried out FMT on her in October
2018. Her Irritable Bowel Syndrome has cleared up completely, energy is beginning to recover.
75%
(F) Age 56 History of Chronic Fatigue Syndrome, Irritable Bowel Syndrome for many years. Resistant to oral approaches for treating both of these conditions.
We carried out FMT in May 2018. Since that time her energy is significantly better, and remains better, bowel function is now normal.
80%
(F) Age 70 Chronic Fatigue Syndrome for many years, also Irritable Bowel Syndrome. We treated her with FMT in October 2017. Bowel habit is now normal,
resistance to intercurrent infections has now returned to normal, energy was consistently improved and remains so.
95%
(M) Age 65 Chronic Fatigue Syndrome for many years. We treated him with FMT in November 2017. Energy has returned to normal. 95%
(F) Age 52 This patient has had Chronic Fatigue Syndrome for many years. Also, Irritable Bowel Syndrome. We treated her with FMT in July 2018. Since then,
her energy has returned to normal and she has now been able to return to work, her gut has also returned to normal.
95%
(F) Age 48 History of Chronic Fatigue Syndrome and Irritable Bowel for many years. We carried out FMT on her in March 2018. Since then her Irritable Bowel
Syndrome has cleared up completely and also her energy has returned to normal.
95%
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